Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 9/20 | 0.48 |
| ▸ | SYK | P43405 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4056007 | 0.88 | AURKA (0.48) | AURKASYKNPC1MAPTPOLB | |
| SCHEMBL4057836 | 0.85 | AURKA (0.46) | AURKASYKNPC1RAB9AMAPT | |
| SCHEMBL4055994 | 0.84 | AURKA (0.48) | AURKASYKNPC1MAPTPOLB | |
| SCHEMBL4064136 | 0.81 | AURKA (0.46) | AURKASYKNPC1RAB9AMAPT | |
| SCHEMBL4058434 | 0.80 | AURKA (0.56) | AURKASYKNPC1RAB9AMAPT | |
| SCHEMBL4058423 | 0.78 | AURKA (0.59) | AURKASYKNPC1RAB9AMAPT | |
| SCHEMBL4062037 | 0.76 | NPC1 (0.48) | AURKASYKNPC1RAB9AMAPT | |
| SCHEMBL4056021 | 0.74 | AURKA (0.46) | AURKASYKMAPTPOLBPKM | |
| SCHEMBL4061109 | 0.69 | AURKA (0.56) | AURKASYKNPC1RAB9AMAPT | |
| SCHEMBL20945087 | 0.67 | NPC1 (0.39) | AURKASYKNPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1794148-B1 | NOVEL PHTHALAZINONE DERIVATIVES, AS AURORA-A KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-04-15 | — | — | EP | disclosed |
| US-7501410-B2 | Methods of inhibiting BTK and SYK protein kinases | ROCHE PALO ALTO LLC (US) | 2009-03-10 | — | — | US | disclosed |
| EP-1998777-A1 | METHODS OF INHIBITING BTK AND SYK PROTEIN KINASES | F. Hoffmann-La Roche AG (CH) | 2008-12-10 | — | — | EP | disclosed |
| WO-2007107469-A1 | METHODS OF INHIBITING BTK AND SYK PROTEIN KINASES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-09-27 | — | — | WO | disclosed |
| US-20070219195-A1 | e.g. 4-(5-Methyl-2H-pyrazole-3-ylamino)-phenyl-2H-phthalazin-1-one2-Phenyl-2,3-dihydro-phthalazine-1,4-dione; tyrosine kinase inhibitor; antiinflammatory agent; asthma, rheumatoid arthritis, systemic lupus erythematosus or multiple sclerosis | ROCHE PALO ALTO LLC | 2007-09-20 | — | — | US | disclosed |
| EP-1794148-A1 | NOVEL PHTHALAZINONE DERIVATIVES, AS AURORA-A KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-06-13 | — | — | EP | disclosed |
| US-7226923-B2 | Phthalazinone derivatives | HOFFMAN-LA ROCHE INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-20060089359-A1 | Phthalazinone derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-27 | — | — | US | disclosed |
| WO-2006032518-A1 | NOVEL PHTHALAZINONE DERIVATIVES, AS AURORA-A KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089359-A1 | Phthalazinone derivatives | SDHA, SDHB, CYP3A5 | AURKA 1585/4885SYK 3513/4885NPC1 549/4885 |
| US-20070219195-A1 | e.g. 4-(5-Methyl-2H-pyrazole-3-ylamino)-phenyl-2H-phthalazin-1-one2-Phenyl-2,3-dihydro-phthalazine-1,4-dione; tyrosine kinase inhibitor; antiinflammatory agent; asthma, rheumatoid arthritis, systemic lupus erythematosus or multiple sclerosis | SYK, BTK, LCK | AURKA 704/4885SYK 1/4885NPC1 4812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.